Modulation of insulin like growth factor I receptor expression

Details for Australian Patent Application No. 2004210882 (hide)

Owner Antisense Therapeutics Pty Ltd

Inventors Werther, George Arthur; Dobie, Kenneth W.; Wraight, Christopher John; Dean, Nicholas M.

Agent Davies Collison Cave

Pub. Number AU-B-2004210882

PCT Pub. Number WO2004/072284

Priority 2003902610 27.05.03 AU; 2003900609 11.02.03 AU

Filing date 11 February 2004

Wipo publication date 26 August 2004

Acceptance publication date 17 September 2009

International Classifications

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61P 17/00 (2006.01) Drugs for dermatological disorders

A61P 35/00 (2006.01) Antineoplastic agents

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

C12N 15/12 (2006.01) Mutation or genetic engineering - Genes encoding animal proteins

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

11 August 2005 PCT application entered the National Phase

  PCT publication WO2004/072284 Priority application(s): WO2004/072284

27 November 2008 Amendment Made

  The nature of the amendment is: Amend the co-inventor name from Dobie, Michael J. to Dobie, Kenneth W.

17 September 2009 Application Accepted

  Published as AU-B-2004210882

21 January 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004210884-The detection and identification of saxiphilins using saxitoxin-biotin conjugates

2004210881-Briquetting process